Multiplex Protein Biomarker Profiling in Patients with Familial Hypercholesterolemia

Area of Science:

• Biochemistry and Molecular Biology
• Cardiovascular Medicine
• Genetics

Background:

• Familial hypercholesterolemia (FH) is a genetic disorder causing high LDL cholesterol.
• It is linked to mutations in genes like LDLR, APOB, PCSK9, and APOE.
• FH significantly increases cardiovascular disease (CVD) risk.

Purpose of the Study:

• To investigate the effects of two distinct therapies on plasma protein biomarkers in FH patients.
• To analyze changes in a broad spectrum of CVD-associated proteins under different treatment regimens.

Main Methods:

• Analysis of plasma samples from FH patients undergoing hypolipidemic therapy (N=18) and combined LDL apheresis/hypolipidemic therapy (N=14).
• Measurement of 184 CVD-associated proteins using proximity extension assay (PEA).
• Statistical analysis to determine significant changes in protein levels (p < 0.01 and p < 0.006).

Main Results:

• Hypolipidemic therapy significantly altered 10 plasma proteins, primarily those involved in vascular endothelial maintenance.
• Combined apheresis/hypolipidemic therapy significantly affected 18 plasma proteins, including those related to cholesterol metabolism and inflammation.
• Specific proteins like ST2 increased with hypolipidemic therapy, while others like LDLR and PCSK9 were affected by combined therapy.

Conclusions:

• Different therapeutic strategies for FH have distinct impacts on plasma protein biomarker profiles.
• Hypolipidemic therapy primarily influences vascular endothelial function markers.
• Combined therapy affects a broader range of proteins, including those central to cholesterol homeostasis and inflammatory pathways in FH management.